Advancing Care of the Failing Heart in the Face of Cancer: Fragile Balance

This session will expand on the HFSA’s scientific statement on Cardio-Oncology, focusing on cancer populations that can benefit from HF clinician involvement. Real-world cases will explore tailored therapeutic approaches, starting with an overview of cancer agents linked to cardiomyopathy and heart failure. The discussion will also cover toxicities related to immune-modulatory cancer therapies, advanced HF therapies in patients with active or prior cancer, permissive toxicity, and the HF clinician’s role in managing advanced cardiac toxicity in cancer patients. The role of VAD/OHT in patients with active cancer will also be explored.

Agenda

• Moderator - Anju Nohria, MD, MSc
• Moderator - Jenica Upshaw, MD
• A Dangerous Mix: Cancer Therapies and the Risk of Heart Failure and Cardiomyopathy - Jacqueline Vo, PhD, RN, MPH
• Living on the Edge: Exploring the Role for Permissive Toxicity in Patients With Stage C HF - Anita Deswal, MD, MPH, FHFSA
• Extinguishing the Fire: Immunotherapy and Myocarditis: When Steroids Might Not Be Enough - Nicolas Palaskas, MD, PhD
• Walking a Tightrope: Advanced Heart Failure and the Role of VAD/OHT in Patients With Active Cancer - Ana Barac, MD PhD
• Panel Discussion